CytoMed Therapeutics Ltd (GDTC) FinancialsGDTCFinancialCytoMed Therapeutics Ltd

Evaluating the bottom line, CytoMed Therapeutics Ltd maintains a gross margin of 32.69%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -1307.27%, while the net margin is -1440.68%. These profitability ratios, combined with a Return on Equity (ROE) of -42.43%, provide a clear picture of how effectively GDTC converts its operational activities into shareholder value.

In the context of the broader market, GDTC competes directly with industry leaders such as LNAI and MTVA. With a market capitalization of $11.79M, it holds a leading position in the sector. When comparing efficiency, GDTC's gross margin of 32.69% stands against LNAI's 100.00% and MTVA's N/A. Such benchmarking helps identify whether CytoMed Therapeutics Ltd is trading at a premium or discount relative to its financial performance.

The stock has a price-to-sales ratio of 13.06, which is relatively high, suggesting that the stock may be overvalued compared to its sales. The negative P/E ratio of -1.91 further indicates that the company is not currently profitable, which is a significant concern for long-term investors.